🔗 Share this article

As the United States continues making unprecedented changes to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning coronavirus vaccines throughout the pandemic and has focused upon alleged deaths after Covid vaccination in her brief position at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Program

Agency leaders had intended to announce radical changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, it is understood – a major change that would put the US out of alignment with many the world with insufficient data for benefit. The planned update has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is listed to speak at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to run the center this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon rolling back previously authorized vaccines at the FDA.

The new acting director has often pushed for discontinuing some childhood immunization guidelines in the US in order to be more similar to the Danish model, a society with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no apparent background in medication creation, regulation or management, which has been typical for previous leaders of the CBER. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She has no expertise in industry regulation.”

Former directors of the center would “be deeply familiar with legal statutes and the science of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who led CBER have had.”

The drug center has an vast workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be managed,” she explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant leadership aspect to the job, which manages in excess of 5,000 employees. “It’s a massive administrative position, if you do it right,” the former official added.

Official Statement and Disputed Programs

In response to inquiries about Høeg’s fitness for the role and whether this appointment represents greater collaboration among agency officials on vaccines, a spokesperson responded that the “concerns rely on incorrect assumptions”.

“This background is consistent with the duties of her position,” the representative said, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial priority voucher program, a disputed expedited medication authorization process that allegedly concerned her former heads. “How are these therapies being picked for this voucher program? Who makes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a more established, if concerning, track record, Howard have noted. She authored a study using unverified public submissions to assess the frequency of myocarditis following Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current government included altering regulations for new vaccines and ending “unnecessary” immunizations, she remarked after the election on a online show. At the FDA, Høeg has according to sources suggested excluding young men from obtaining Covid vaccines.

“She’s an all-around true believer who starts off with her beliefs and reverse-engineers to retrofit the data in a highly misleading, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|